A request for proposals for modeling population benefit versus individual risk (benefit-risk assessments) for the tetravalent live attenuated dengue vaccine developed by Takeda (TAK-003).
Please visit the United Nations Global Market website for more information: https://www.ungm.org/Public/Notice/194314 .
